Invizius

Invizius’s Pioneering Dialysis Product H-Guard Completes First In-Human Clinical Study  

Study demonstrated safety and tolerability of H-Guard, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubule cell damage during Continuous Renal Replacement Therapy (CRRT). 22 May 2024 -- Manchester, UK --...
Suite 2, Ground Floor Orchard Brae House, 30 Queensferry Road, Edinburgh, United Kingdom, EH4 2HS